Drug Profile
Lerapolturev - Istari Oncology
Alternative Names: Polio Virus Sabin-Rhinovirus Poliovirus; PVS-RIPO; Re-engineered poliovirus; Recombinant-polio-virus-vaccine-Istari-Oncology; Sabin type 1 polio vaccine - Istari OncologyLatest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Duke University Medical Center
- Developer Duke University Medical Center; Istari Oncology; National Cancer Institute (USA)
- Class Antineoplastics; Attenuated vaccines; Cancer vaccines; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma; Malignant melanoma
- Phase I/II Solid tumours
- No development reported Breast cancer; Prostate cancer
Most Recent Events
- 20 Dec 2023 Istari Oncology plans a phase II trial for Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in USA (Intratumoral) (NCT06177964)
- 18 Oct 2022 Efficacy data from a phase II LUMINOS-102 trial in Metastatic melanoma released by Istari Oncology
- 28 Aug 2022 No recent reports of development identified for phase-I development in Glioblastoma(In adolescents, In children, Recurrent, Second-line therapy or greater) in USA (Intratumoural, Infusion)